In the present study, a design of experiment (DoE) approach was used to optimize chromatographic conditions for the development of a high-performance thin-layer chromatography (HPTLC) method for the simultaneous estimation of metformin hydrochloride (MET) and ursodeoxycholic acid (URSO) in pharmaceutical dosage form. The critical factors were identified using a Taguchi design, and after identification of critical factors, optimization was done using Box-Behnken design (BBD). BBD was used to optimize the compositional parameters and to evaluate the main effect, interaction effects, and quadratic effects of the mobile phase compositions, development distance, and saturation time on the retardation factor (RF) of both drugs. HPTLC separation was performed on aluminum plates pre-coated with silica gel 60 F254 as the stationary phase, using toluene–ethanol–acetone–formic acid (4.5:2:2.5:0.85, V/V) as the mobile phase at a wavelength of 234 nm and 700 nm for MET and URSO, respectively. A sharp and well-resolved peak was obtained for MET and URSO at RF values of 0.19 and 0.80 min, respectively. The calibration curve was in the range of 5000–40000 ng per spot and 1500–12000 ng per spot for MET and URSO, with r2 = 0.984 and r2 = 0.980, respectively. The method was validated for linearity, accuracy, precision, limit of detection, limit of quantification, and specificity. To provide a better visualization of the statistically significant factors derived from the statistical analysis, the perturbation plot and response surface plot for the effect of independent variables on the RF of MET and URSO were evaluated. Stability study was performed under different stress conditions such as acid and alkali hydrolysis, oxidation, and temperature. The developed method was able to resolve drugs and their degradation products formed under the afore-mentioned conditions.
K.D. Tripathi , Essential medical pharmacology, 6th edn., Jaypee Brothers Medical Publishers (P) Ltd., New Delhi, 2008, p. 254–255.
A. Roda , A. Giocchini, A. Marietta, C. Cerre, M. Montagnani, A. Fini, J. Gastroenterol. 27 (1995) 327–331.
J. Maryadele , O. Neil, The Merck Index: an encyclopedia of chemicals, drugs and biological, 15th edn., Merck Research Laboratories, Whitehouse Station, NJ, 2013.
H.P. Chhetri , P. Thapa, A. V. Schepdael, Simple HPLC-UV method for the quantification of metformin in human plasma with one step protein precipitation, Saudi Pharm. J. 22 (2014) 483–487.
B.S. Rao , S.S. Dubey, N.K. Rao, V.B. Kiran, Development and validation of reverse phase RP-HPLC method for the determination of metformin HCl in pharmaceutical dosage forms, Asian J. Chem. 24 (2012) 5460–5462.
Y. Harahap , K. Dianpratami, M. Wulandari, R. Rahmawati, Validation of metformin hydrochloride in human plasma by HPLC-photo diode array (PDA) for application of bioequivalence study, J. Life Sci. 6 (2012) 20–27.
J. Mukherjee , T.K. Pal, Development and validation of RP-HPLC method to determine ursodeoxycholic acid in pharmaceutical dosage forms, Int. J. Pharm. Sci. Res. 2 (2011) 71–73.
M. Kar , P.K. Choudhury, HPLC method for estimation of metformin hydrochloride in formulated microspheres and tablet dosage form, Indian J. Pharm. Sci. 71 (2009) 318–320.
A. Peepliwal , K.G. Bothara, A validated RP-HPLC method for quantitative determination of related impurities of ursodeoxycholic acid (API) by refractive index detection, J. Pharm. Biomed. Anal. 54 (2011) 845–849.
M. Reddy , G. Mubeen, M. Pal, HPTLC method for estimation of metformin hydrochloride, Biomed. Pharmacol. J. 1 (2016) 2–5.
R. Miral , K. Pankaj, S. Ketan, Development and validation of stability indicating HPTLC method for pioglitazone hydrochloride and metformin hydrochloride, Res. J. Pharm. Tech. 9 (2016) 1555–1561.
P. Jain , D. Girase, A. Bedse, S. Surana, Stability indicating HPTLC densitometry method for determination of metformin hydrochloride in tablet formulation, J. Pharm. Biosci. 2 (2013) 51–58.
S. Gurule , D. Goswami, A. Saha, Y. Modhave, A.K. Monif, Bioanalytical method development and validation using incurred samples: Quantitative estimation of metformin in human K3EDTA plasma by LC-MS/MS, Clin. Res. Regul. Aff. 29 (2012) 1–3.
D. Michela , C.M. Gauntb, T. Arnasonc, A. Elaneeda, Development and validation of fast and simple flow injection analysis-tandem mass spectrometry (FIA-MS/MS) for the determination of metformin in dog serum, J. Pharm. Biomed. Anal. 107 (2015) 229–235.
K. Noor , G. Mubeen, Spectrophotometric method for analysis of metformin hydrochloride, Indian J. Pharm. Sci. 71 (2009) 100–102.
P. Mahadik , D. Dahia, T. Mani, P. Gaikwad, S. Gavali, Method development and validation of metformin in bulk and pharmaceutical dosage forms by using spectrophotometric method, Am. J. Pharm. Tech. Res. 2 (2012) 350–355.
J.A. Wass , First steps in experimental design - The screening experiment, J. Valid. Technol. 16 (2010) 46–53.
V.P. Patel , H.D. Shihora, Experimental design and patent, 1st edn., Akshat Publication, Gujarat, 2011, 1–35.
G.E.P. Box , N.R. Draper, Response surfaces, mixtures, and ridge analyses, 2nd edn., John Wiley & Sons, Hoboken, NJ, 2007, 129–200.
M. Bakshi , S. Singh, Development of validated stability-indicating assay methods – critical review, J. Pharm. Biomed. Anal. 28 (2002) 1011–1040.
ICH , Stability Testing for New Dosage Forms in International Conference on Harmonization, IFPMA, Geneva, 1996.
ICH , Q2 (R1) Validation of Analytical Procedures: Text and Methodology, International Conference on Harmonization, IFPMA, Geneva, 2005.